Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

• Published in: bioRxiv
• Main Authors: Ying, Baoling, Whitener, Bradley, VanBlargan, Laura A, Hassan, Ahmed O, Shrihari, Swathi, Liang, Chieh-Yu, Karl, Courtney E, Mackin, Samantha, Chen, Rita E, Kafai, Natasha M, Wilks, Samuel H, Smith, Derek J, Carreño, Juan Manuel, Singh, Gagandeep, Krammer, Florian, Carfi, Andrea, Elbashir, Sayda, Edwards, Darin K, Thackray, Larissa B, Diamond, Michael S
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 26.08.2021; Cold Spring Harbor Laboratory
• Edition: 1.1
• Subjects: Biotechnology; Bronchopulmonary infection; COVID-19; Immunization; Immunogenicity; Lymphocytes T; Microbiology; mRNA; mRNA vaccines; Patent applications; Severe acute respiratory syndrome coronavirus 2
• ISSN: 2692-8205; 2692-8205
• DOI: 10.1101/2021.08.25.457693

Although mRNA vaccines prevent COVID-19, variants jeopardize their efficacy as immunity wanes. Here, we assessed the immunogenicity and protective activity of historical (mRNA-1273, designed for Wuhan-1 spike) or modified (mRNA-1273.351, designed for B.1.351 spike) preclinical Moderna mRNA vaccines in 129S2 and K18-hACE2 mice. Immunization with high or low dose formulations of mRNA vaccines induced neutralizing antibodies in serum against ancestral SARS-CoV-2 and several variants, although levels were lower particularly against the B.1.617.2 (Delta) virus. Protection against weight loss and lung pathology was observed with all high-dose vaccines against all viruses. Nonetheless, low-dose formulations of the vaccines, which produced lower magnitude antibody and T cell responses, and serve as a possible model for waning immunity, showed breakthrough lung infection and pneumonia with B.1.617.2. Thus, as levels of immunity induced by mRNA vaccines decline, breakthrough infection and disease likely will occur with some SARS-CoV-2 variants, suggesting a need for additional booster regimens.